| Hepatitis C Virus |
1 |
1 |
| Hepatitis |
0 |
0.58 |
| Hepatitis A |
0 |
0.51 |
| Protease Inhibitor |
0 |
0.43 |
| Liver |
0 |
0.41 |
| Addiction |
0 |
0.37 |
| Liver Disease |
0 |
0.36 |
| Adverse Effects |
0 |
0.31 |
| Preventive Screening |
0 |
0.31 |
| Proteases |
0 |
0.31 |
| Biliary Disease |
0 |
0.17 |
| Electronic Medical Record |
0 |
0.14 |
| Substance Abuse |
0 |
0.14 |
| Pregnancy |
0 |
0.13 |
| Patient Safety |
0 |
0.12 |
| Abuse |
0 |
0.1 |
| Cirrhosis |
0 |
0.1 |
| Clinical Guidelines |
0 |
0.1 |
| Drug Costs |
0 |
0.1 |
| Drug Development |
0 |
0.1 |
| Food and Drug Administration (FDA) |
0 |
0.1 |
| Georgia |
0 |
0.1 |
| Medical Records |
0 |
0.1 |
| Pegylated Interferon |
0 |
0.1 |
| Point-of-Care |
0 |
0.1 |
| Polymerase Chain Reaction |
0 |
0.1 |
| Primary Care |
0 |
0.1 |
| Psychosocial |
0 |
0.1 |
| Salary and Compensation |
0 |
0.1 |
| Spine |
0 |
0.1 |